Not Signed In -
Infliximab |
Remicade |
Clinical Trial: Study of Remicade (Infliximab) in Psoriatic Arthritis
This study has been completed.
|
Purpose
To assess the effectiveness and safety of infliximab for use in active Psoriatic Arthritis
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Psoriatic Arthritis | Drug: Infliximab | Phase III |
MedlinePlus related topics: Arthritis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Safety/Efficacy Study
Official Title: A Multicenter, Randomized, Double-blind Trial of Anti-TNF alpha Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Subjects with Psoriatic Arthritis
Further Study Details:
Expected Total Enrollment: 200
Study start: December 2002; Study completion: July 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion:
- Psoriatic Arthritis diagnosed at least 6 months ago
- Active psoriasis and five tender and swollen joints
- Age 18 years or older
- Can be using MTX, but not required. If using MTX, must be taking it for the last 3 months or longer
Exclusion:
- Treatment with anti-TNF agents in the past
- Chronic or recurrent infections
- A major medical problem
Location Information
Alabama
Huntsville, Alabama, United States
California
Rancho Cucamonga, California, United States
Los Angeles, California, United States
Palo Alto, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Colorado
Denver, Colorado, United States
Florida
Delray Beach, Florida, United States
Maryland
Wheaton, Maryland, United States
Greenbelt, Maryland, United States
Massachusetts
Worcester, Massachusetts, United States
Michigan
Lansing, Michigan, United States
New Jersey
New Brunswick, New Jersey, United States
New York
New York, New York, United States
North Carolina
Wilmington, North Carolina, United States
Oklahoma
Oklahoma City, Oklahoma, United States
Pennsylvania
Lancaster, Pennsylvania, United States
Texas
Houston, Texas, United States
Dallas, Texas, United States
Utah
Salt Lake City, Utah, United States
Virginia
Norfolk, Virginia, United States
Washington
Seattle, Washington, United States
Canada, Ontario
Toronto, Ontario, Canada
New Market, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
More Information
National Psoriasis Foundation
CenterWatch
Study ID Numbers: CO168T50
Record last reviewed: August 2003
Last Updated: October 13, 2004
Record first received: January 14, 2003
ClinicalTrials.gov Identifier: NCT00051623
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: August 2003
Last Updated: October 13, 2004
Record first received: January 14, 2003
ClinicalTrials.gov Identifier: NCT00051623
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Infliximab (Drug Digest)
- Remicade (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
